Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Elliott

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 1, 1994
Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damageR T Bartus, K L Baker, A D Heiser, et al.
Neurological Research|August 1, 1995
Calpain as a novel target for treating acute neurodegenerative disordersR T Bartus, P J Elliott, N J Hayward, et al.
Journal of Cellular Biochemistry|June 16, 2001
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerS A Shah, M W Potter, T P McDade, et al.
Journal of Neuro-Oncology|April 2, 1998
Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brainJ R Fike, G T Gobbel, A H Mesiwala, et al.
Experimental Neurology|November 1, 1996
Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7R T Bartus, P J Elliott, R L Dean, et al.
Neurotoxicity Research|January 13, 2004
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the ratR Berti, A J Williams, L C Velarde, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 18, 2011
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamicsLynne M Howells, D P Berry, P J Elliott, et al.
Cancer Research|June 11, 1999
Proteasome inhibitors: a novel class of potent and effective antitumor agentsJ Adams, V J Palombella, E A Sausville, et al.
Regulatory Peptides|July 2, 1993
Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonistsR M Hagan, I J Beresford, J Stables, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1979
Open and comparative treatment studies with tetroxoprim/sulphadiazine combinations in urinary infections (1975--1979)D S Reeves, A J Bint, R Bowman, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 1, 1994
Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damageR T Bartus, K L Baker, A D Heiser, et al.
Neurological Research|August 1, 1995
Calpain as a novel target for treating acute neurodegenerative disordersR T Bartus, P J Elliott, N J Hayward, et al.
Journal of Cellular Biochemistry|June 16, 2001
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerS A Shah, M W Potter, T P McDade, et al.
Journal of Neuro-Oncology|April 2, 1998
Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brainJ R Fike, G T Gobbel, A H Mesiwala, et al.
Experimental Neurology|November 1, 1996
Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7R T Bartus, P J Elliott, R L Dean, et al.
Neurotoxicity Research|January 13, 2004
Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the ratR Berti, A J Williams, L C Velarde, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 18, 2011
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamicsLynne M Howells, D P Berry, P J Elliott, et al.
Cancer Research|June 11, 1999
Proteasome inhibitors: a novel class of potent and effective antitumor agentsJ Adams, V J Palombella, E A Sausville, et al.
Regulatory Peptides|July 2, 1993
Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonistsR M Hagan, I J Beresford, J Stables, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 1979
Open and comparative treatment studies with tetroxoprim/sulphadiazine combinations in urinary infections (1975--1979)D S Reeves, A J Bint, R Bowman, et al.
Pageof 8